Despite a lack of evidence of clinical benefit and substantial safety and quality concerns, an FDA advisory committee ...

Many details of these agreements remain undisclosed, but what we know suggests they may be less far-reaching than claimed.

The advent of cell and gene therapies heralds a powerful shift, but without deliberate attention to financing, delivery, data ...

Congress should give employers a more accountable and affordable option to administer their medical benefit plans.

The concept rests on assumptions that are unsupported by evidence. Consequently, current proposals for mandatory ...

As HHS Secretary, Robert F. Kennedy Jr. has selectively cherry-picked many of his long-standing interests and their purported ...

Understanding the impact of price controls on drug research and approvals of secondary indications is critical for policy ...

The current MA risk adjustment model has shortcomings, both in predictive accuracy and payment equity across the Medicare ...

What California chooses in the next six months will determine whether a decade of Medicaid transformation holds or collapses ...

The rapid growth of private equity (PE) and publicly traded corporation (PTC) ownership in hospice has raised concerns that investor-driven profit incentives may undermine care quality. Evidence on ...

Responding to patient-initiated portal messages is a growing source of work for physicians, yet little is known about how these messages are distributed across patients and physicians. Understanding ...

The Medicare Drug Price Negotiation Program exempts or delays negotiation for drugs with orphan indications. Whether these protections are necessary to sustain orphan drug development is unclear. We ...